New Website Intended to Communicate the Company’s Vision and Technology

LANSING, Mich., July 22, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today announced the launch of its entirely new website, www.kraiglabs.com.

“Although we’ve worked with cutting-edge biotech companies in the past, our whole team was fascinated by the incredible things Kraig Biocraft is achieving in the labs,” commented Jonathan Keim, owner of GPGSolutions. “We truly enjoyed working with the Company and being a part of its exciting story.”

“As we move toward the commercialization of recombinant spider silks, it is important that we build our band and our image,” said Company CEO and founder, Kim K Thompson. “With Jonathan’s help, we built a website from the ground up, to better highlight the Company’s high-tech foundations and enhance our public image. The new and improved website is also part of our plan to improve communication with prospective partners, customers and our shareholders. We hired GPGSolutions’ because of their stellar reputation and their enthusiasm for the project. Their creativity, responsiveness and technical ability worked to produce a platform that better represents our vision and promotes our brand.”

Shareholders and interested persons who have not already done so, are invited to subscribe to the Company’s email updates in advance of the launch of that program. The sign in button can be found at the bottom of the Investors page of the Company website.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Contact:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., July 15, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of advanced spider silk based fibers, today announced that it is scheduled to start commercial production of Monster Silk™.

The first phase, scheduled to begin within the next three weeks, will be focused on establishing commercial scale production capacity. “We have been laying the ground work for commercial production over the last six months with our pilot production program,” said Company CEO and founder, Kim K Thompson. “We have moved cautiously and prudently in testing our methods and procedures. It’s now time to convert the pilot program to commercial production.”

The launch of commercial production follows on the heels of the Company’s pilot production program which has been running since January.

“The successful scale-up to commercial production is a significant milestone for any company,” continued Thompson, “and, considering the importance we place on Monster Silk™, I have to agree that this is a momentous step for Kraig. It is especially exciting because we are creating what we believe will be the world’s first commercial scale production of recombinant spider silk.”

While the Company is creating this production capacity, it is in discussions with one or more other countries about further expanding and diversifying its production capacity for Monster Silk™.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., July 8, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Kraig”), the leading developer of advanced spider silk based fibers, today announced plans to add key personnel, in order to support its production growth strategy and expand its ability to service potential clients as Kraig grows.

Kraig is looking to add two talented and experienced individuals to its team, to help with a wide array of responsibilities, ranging from operations to market development.

The fundamental considerations include a balanced mix of qualifications, experience and reputation.

“We’re looking for key individuals, to work as part of a cooperative team to accelerate the Company’s growth in 2013 and beyond,” stated Company CEO and founder, Kim K Thompson. “In addition to improving organizational effectiveness, I welcome the addition of valuable perspective and insight that these key hires may add to our organization. Frankly, as we transition from being a research and development company to the commercialization of new recombinant fibers, we need to add more hands on deck to take on the increased responsibilities. I am thrilled to be adding to our executive team to help guide our product development, sales and marketing, and technological efforts.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., July 1, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company”), the leading developer of advanced spider silk based fibers, today announced the end of the quiet period phase related to its recently filed S1 financing registration and a second potential financing that the Company has now terminated.

“We are very happy to be able to announce the end of this quiet period, and we want to thank our shareholders for their patience,” said Company CEO and founder, Kim K Thompson. “Quiet periods during times when certain financings are being prepared are a normal part of the Company’s regulatory compliance obligations. While it is wonderful to receive the underlying finance, the quiet periods themselves are an unwelcome, but necessary burden. Having successfully carried that burden, we are now very happy to set it down.”

During the quiet period, the Company was unable, from its perspective, to effectively disseminate corporate information announcements and public relations announcements. The Company had come to terms with a New York based investment banking firm for a potential financing (in addition to the financing described in the recently filed S1) that would have necessitated a second S1 registration. The Company has determined however that the burden of an additional quiet period, or any further open ended extension of the quiet period, would be too counterproductive. The Company is looking forward to resuming more open communications with the financial markets and shareholders.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., May 7, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company”), the leading developer of advanced spider silk based fibers, today announced plans to launch its initial commercial production of Monster Silk™. The announcement of the Company’s decision to launch commercial production follows the early successes of its of Monster Silk™ pilot production program.

“We have received strong indications of interest from potential customers and potential commercialization partners,” said, CEO and founder, Kim Thompson. “Many of these companies have been very patient with the fact that our laboratory production has been limited and can not satisfy their demand for quantities of material sufficient to run test weaves and end product testing.

“Moving from our pilot production program to commercial production is a very big jump, but it is also a natural progression,” continued Thompson. “We have been laying the groundwork for this expansion over the last twelve months. We are confident in the decision and we are hopeful that we can accomplish the launch during the third and fourth quarters. Our plan is to begin commercial production to meet customer needs, secure future orders and capture market share in the technical textiles market.”

Kraig’s pilot production program will continue to run, in order to supply continuing data and help grow the Company’s production capacity.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., April 17, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company”), the leading developer of advanced spider silk based fibers, announced today that all of the Board of Director’s proposals were approved at its meeting of shareholders held yesterday in Lansing, Michigan.

All three amendments to Company’s charter listed on the meeting agenda passed with unanimous attending shareholder approval. The amendments were designed to help management advance the business model in a more streamlined fashion.

“The overwhelming support of the attending shareholders, expressed over nearly four hours of discussions, and the unanimous vote on all of management’s proposals, is a validation of our plans for production and commercialization,” said CEO and founder Kim Thompson. “I am looking forward to communicating further details of our plans and progress to the shareholders in an upcoming shareholder conference call.”

“I would like to thank the shareholders who were able to take time out of their busy schedules to attend the meeting,” continued Thompson. “It was extremely gratifying to meet other shareholders, who share many of the same visions and goals for the Company and the technology.”

A copy of the three amendments to the Company charter which were approved by the shareholders at yesterday’s meeting is available on the Company’s website under the notice of meeting section.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., April 3, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company”), the leading developer of advanced spider silk based fibers, will hold a shareholder meeting on April 16, 2013. Along with the notice of meeting, the Company’s founder and CEO, Kim K Thompson has posted a letter to the shareholders on the Company’s website.

“We plan to continue accelerating our commercial development through 2013 and beyond,” said CEO and founder Kim K Thompson. “We will also be announcing a shareholder conference call to be held sometime after the shareholders’ meeting, to discuss our progress and ambitious plans for 2013 and 2014.”

To view the letter to shareholders as well as the notice of the shareholder meeting along with details regarding the meeting please go to www.KraigLabs.com. The letter to shareholders and the notice of the shareholder meeting are also being provided to shareholders through electronic communication, for those who have previously opted for electronic communication or through the US postal service.

Furthermore, the Company is inviting shareholders to join the Kraig e-mail alert list, which will allow the Company to communicate more effectively with its shareholder community. For periodic updates, notices and important press releases, please subscribe by sending an email containing the words “shareholder, add me to the list” to Shareholder@KraigLabs.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., March 25, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company”), the leading developer of advanced spider silk based fibers, announced today that Dr. Malcolm Fraser, PhD, an influential member of the Company’s scientific advisory board, is in India meeting with scientists, government officials and industry. The Company’s CEO and Founder, Kim Thompson, is also traveling and is currently in another country meeting with government officials and businessmen to discus and explore production and processing opportunities for Monster Silk™ and other recombinant spider silks.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., March 19, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fibers, announced today that the cocoons from the first stage of its Monster Silk™ pilot production program (“program”) have been reeled into threads of the Company’s recombinant spider silk as the program moves into an advanced state.

Additionally, the silkworm hatchlings from the second stage of the program have now spun cocoons that are made of Monster Silk™.

“The pilot production program has advanced well ahead of our expectations. At this rate, we will be facing some near term decisions regarding the launching of commercial production. In my opinion, we are now reaching major milestones every two to three weeks. We are undergoing tremendous developmental changes, which we believe will lead to substantial growth of our business over the next few months,” said Company founder and CEO, Kim Thompson.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com

LANSING, Mich., March 12, 2013 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the “Company” or “Kraig”), the leading developer of advanced spider silk based fibers, announced today that the Company has received an invitation from the council office of a foreign country to visit that country. The purpose of the invitation is to meet with governmental officials to discuss and explore the potential to produce the Company’s recombinant spider silk there.

“It is a great honor for Kraig to receive this diplomatic invitation,” said Company founder and CEO, Kim Thompson. “It also represents a unique opportunity. We have accepted the invitation to visit a potential production location and to meet with officials to discuss the business opportunities presented.”

The Company’s CEO anticipates traveling to that country and exploring the production possibilities within the next three weeks.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com